REPL

Replimune Group, Inc.

Biotechnology · Biotechnology

$133.98 sample

+2.33 (+1.77%) 1D

Market cap

$563.7B

Price as of

2026-10-15

Latest filing

8-K

Alerts

8

Price$133.98 +16.69% 3M daily closessample

133.98114.64

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 12INSInsider sell: Director
Oct 05INSInsider sell: EVP, Operations
Sep 24INSInsider buy: Chief Financial Officer
Sep 21INSInsider sell: Chief Executive Officer
Sep 11INSInsider sell: EVP, Operations
Sep 08INSInsider sell: Chief Financial Officer
Aug 31INSInsider buy: Chief Financial Officer
Aug 24INSInsider sell: Chief Financial Officer

Sign up to see the real REPL record →

Company facts

SEC EDGAR registration

Name: Replimune Group, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: +38sample, -100 to +100
Reporting currency: USD

Who is positioning in REPL

sample

Insiders: 16 insider transactions over 90 days, net selling, $230.0M
Congress: 2 members traded over 90 days
Institutions · 13F: 44 funds hold $11.4B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$30.9B +13.4% y/y

Q4 2024Q3 2026

Inventory$18.8B +14.9% y/y

Q4 2024Q3 2026

Accounts receivable$14.6B +20.5% y/y

Q4 2024Q3 2026

Total debt$37.6B +8.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $79.5B +13.2% 3M
Sample peer B: $149.0B -2.6% 3M
Sample peer C: $387.1B +12.4% 3M
Sample peer D: $87.4B +10.2% 3M
Sample peer E: $95.3B +15.3% 3M